Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: A case report.
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: A case report.
复制标题
S-1 在接受达沙替尼治疗的患有慢性粒细胞白血病的复发性结肠癌患者中的安全性和药代动力学：病例报告。
DOI：
10.1007/s00280-014-2620-8
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Satoh T.
中科院分区：
文献类型：
--
作者：
Sueda T.;Kudo T.;Sakai D.;Uemura M.; Nishimura J.;Hata T.; Takemasa I.; Mizushima T.;Yamamoto H.; Ezoe S.; Matsumoto K.;Doki Y.; Mori M.; Satoh T.
目的：S-1治疗复发性结直肠癌伴慢性粒细胞白血病（CML）患者达沙替尼治疗的安全性尚未确定。我们评估了S-1在一名复发性结肠癌CML患者中的安全性和药代动力学，该患者为一名70岁的男性，因乙状结肠癌和复发接受了三次手术。由于转移性结肠癌，已经进行了S-1+奥沙利铂+贝伐珠单抗全身化疗（作为临床试验）。患者病史为CML，一直接受达沙替尼治疗（100 mg，每日一次）。基于不可切除和多发性转移的诊断，开始S-1单药治疗。连续28天服用S-1（120 mg/天），然后停药14天。在S-1首次给药前后采集血样。结果替加氟（FT）、5-氯-2，4-二羟基吡啶（CDHP）、氧氟沙星（Oxo）和5-氟尿嘧啶（5-FU）的药时曲线下面积（AUC 0 -8）分别为4，309.2，716.3，86.8和492.75 ng h/mL; S-1给药后S-1治疗后FT、CDHP、Oxo和5-FU的药代动力学与S-1的I期药代动力学研究无显著差异。在S-1和达沙替尼治疗期间，CML复发和严重的骨髓抑制没有observed.ConclusionsOur报告表明，S-1是一个重要的治疗选择复发性结直肠癌患者与达沙替尼治疗CML。
PurposeThe safety of S-1 in recurrent colorectal cancer patients with chronic myeloid leukemia (CML) treated with dasatinib has not been established. We evaluated the safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with CML treated with dasatinib.PatientA 70-year-old man had undergone surgery three times for sigmoid colon cancer and recurrence. Systemic chemotherapy with S-1 plus oxaliplatin plus bevacizumab as a clinical trial had already been administered because of metastatic colon cancer. The patient’s medical history was CML, and he had been receiving dasatinib treatment (100 mg once daily). Based on the diagnosis of unresectable and multiple metastases, S-1 monotherapy was started. S-1 (120 mg/day) was taken for 28 consecutive days, followed by a 14-day rest. Blood samples were obtained before and after the first administration of S-1. The plasma pharmacokinetics of S-1 were comparable to a pharmacokinetics study of S-1.ResultsThe area under the plasma concentration–time curve (AUC0–8) of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (CDHP), oxonate (Oxo), and 5-fluorouracil (5-FU) was 4,309.2, 716.3, 86.8, and 492.75 ng h/mL, respectively, after S-1 administration. The pharmacokinetics of FT, CDHP, Oxo, and 5-FU after treatment with S-1 were not significantly different from a phase I pharmacokinetics study of S-1. During treatment with S-1 and dasatinib, CML relapse and serious myelosuppression were not observed.ConclusionsOur report suggests that S-1 is an important treatment option for recurrent colorectal cancer in patients with CML treated with dasatinib.